SCHEMBL30274282

SCHEMBL30274282

O=C1c2ccccc2C(=O)N1CCOCCOCCO

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
GAA P10253 1/20 0.51
HPGD P15428 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
RAB9A P51151 6/20 0.50
NPC1 O15118 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 1/20 0.50
GLA P06280 1/20 0.49
BRCA1 P38398 1/20 0.49
GLS O94925 1/20 0.49
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
HEXA P06865 1/20 0.47
HEXB P07686 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26813895 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL26101354 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL30392446 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL30392640 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL3892107 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL23720311 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL19541802 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL5371487 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL230525 1.00 SMN1; SMN2 (0.54) SMN1; SMN2GAAHPGDNPSR1RAB9A
SCHEMBL30274320 0.98 SMN1; SMN2 (0.55) SMN1; SMN2GAAHPGDNPSR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 EP disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 EP disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
US-20240336642-A1 INHIBITORS OF 12/15-LIPOXYGENASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-10-10 US disclosed
CN-118382435-A 12/15-Lipoxygenase inhibitors 总医院公司 2024-07-23 CN disclosed
EP-4384161-A1 INHIBITORS OF 12/15-LIPOXYGENASE The General Hospital Corporation (US) 2024-06-19 EP disclosed
WO-2023019090-A1 INHIBITORS OF 12/15-LIPOXYGENASE THE GENERAL HOSPITAL CORPORATION (US) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 SMN1; SMN2 1897/4885GAA 2767/4885HPGD 3257/4885
US-20240336642-A1 INHIBITORS OF 12/15-LIPOXYGENASE ALOX15, LOX, ALOX12 SMN1; SMN2 729/4885GAA 647/4885HPGD 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.